Inhibition of hepatitis B virus replication in vivo using lipoplexes containing altritol-modified antiviral siRNAs
Artificial DNA: PNA & XNA · 2010
DOI: 10.4161/adna.1.1.11981 ↗Kurz gefasst
Fachartikel in der Zeitschrift Artificial DNA: PNA & XNA, 2010. Verfasst von Justin Hean und 14 weiteren Autor:innen. Beteiligte Einrichtung: Antiviral Gene Therapy Research Unit; School of Pathology; University of the Witwatersrand Medical School; South Africa. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Chronic infection with the hepatitis B virus (HBV) occurs in approximately 6% of the world's population and carriers of the virus are at risk for complicating hepatocellular carcinoma. Current treatment options have limited efficacy and chronic HBV infection is likely to remain a significant global medical problem for many years to come. Silencing HBV gene expression by harnessing RNA interference (RNAi) presents an attractive option for development of novel and effective anti HBV agents. However, despite significant and rapid progress, further refinement of existing technologies is necessary before clinical application of RNAi-based HBV therapies is realized. Limiting off target effects, improvement of delivery efficiency, dose regulation and preventing reactivation of viral replication are some of the hurdles that need to be overcome. To address this, we assessed the usefulness of the recently described class of altritol-containing synthetic siRNAs (ANA siRNAs), which were administered as lipoplexes and tested in vivo in a stringent HBV transgenic mouse model. Our observations show that ANA siRNAs are capable of silencing of HBV replication in vivo. Importantly, non specific immunostimulation was observed with unmodified siRNAs and this undesirable effect was significantly attenuated by ANA modification. Inhibition of HBV replication of approximately 50% was achieved without evidence for induction of toxicity. These results augur well for future application of ANA siRNA therapeutic lipoplexes.
Autor:innen und Institutionen
- Antiviral Gene Therapy Research Unit; School of Pathology; University of the Witwatersrand Medical School; South Africa.
Zitieren
APA
Hean, J., Crowther, C., Ely, A., Ul Islam, R., Barichievy, S., Bloom, K., Weinberg, M. S., van Otterlo, W. A., de Koning, C. B., Salazar, F., Marion, P., Roesch, E. B., Lemaitre, M., Herdewijn, P., & Arbuthnot, P. (2010). Inhibition of hepatitis B virus replication in vivo using lipoplexes containing altritol-modified antiviral siRNAs. Artificial DNA: PNA & XNA. https://doi.org/10.4161/adna.1.1.11981
Vancouver
Hean J, Crowther C, Ely A, Ul Islam R, Barichievy S, Bloom K, et al. Inhibition of hepatitis B virus replication in vivo using lipoplexes containing altritol-modified antiviral siRNAs. Artificial DNA: PNA & XNA. 2010. doi:10.4161/adna.1.1.11981
BibTeX
@article{Hean2010,
author = {Hean, Justin and Crowther, Carol and Ely, Abdullah and Ul Islam, Rafique and Barichievy, Samantha and Bloom, Kristie and Weinberg, Marc S and van Otterlo, Willem Al and de Koning, Charles B and Salazar, Felix and Marion, Patricia and Roesch, Eric B and Lemaitre, Marc and Herdewijn, Piet and Arbuthnot, Patrick},
title = {Inhibition of hepatitis B virus replication in vivo using lipoplexes containing altritol-modified antiviral siRNAs},
journal = {Artificial DNA: PNA & XNA},
year = {2010},
doi = {10.4161/adna.1.1.11981}
}
EUVIMED